Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells

Haematologica

Volumn 98, Issue 1, 2013, Pages 31-40

  Hechinger, Anne Kathrin ^a,b   Maas, Kristina ^a   Dürr, Christoph ^a,b   Leonhardt, Franziska ^a,b   Prinz, Gabriele ^a   Marks, Reinhard ^a   Gerlach, Ulrike ^a   Hofmann, Maike ^b   Fisch, Paul ^a   Finke, Jürgen ^b   Pircher, Hanspeter ^b   Zeiser, Robert ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GGTI 2133; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; N [[5 [(2 AMINO 3 MERCAPTOPROPYL) AMINO] [1, 1' BIPHENYL] 2 YL] CARBONYL] METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; TRANSFERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZARAGOCIC ACID A;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LEUKEMIA; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DISEASE SEVERITY; EFFECTOR CELL; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN FARNESYLATION; PROTEIN GERANYLGERANYLATION; PROTEIN MODIFICATION; THYMUS FUNCTION; WESTERN BLOTTING;

ANIMALS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PRENYLATION; PROTEIN PRENYLATION; QUINOLONES; TREATMENT OUTCOME;

EID: 84872072427     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.065789     Document Type: Article

References (44)

1. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11(18):2295-322.
2. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65: 241-69.
3. Na HJ, Lee SJ, Kang YC, ChoYL, Nam WD, Kim PK, et al. Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation. J Immunol. 2004;173(2):1276-83.
4. Gaylo AE, Laux KS, Batzel EJ, Berg ME, Field KA. Delayed rejection of MHC class II-disparate skin allografts in mice treated with farnesyltransferase inhibitors. Transpl Immunol. 2009;20(3):163-70.
5. Sung ND, Cho YK, Kwon BM, Hyun KH, Kim CK. 3D QSAR studies on cinnamaldehyde analogues as farnesyl protein transferase inhibitors. Arch Pharm Res. 2004;27(10):1001-8.
6. Koh WS, Yoon SY, Kwon BM, Jeong TC, Nam KS, Han MY. Cinnamaldehyde inhibits lymphocyte proliferation and modulates T-cell differentiation. Int J Immunopharmacol. 1998;20(11):643-60.
7. Si MS, Ji P, Tromberg BJ, Lee M, Kwok J, Ng SC, Imagawa DK. Farnesyltransferase inhibition: a novel method of immunomodulation. Int Immunopharmacol. 2003;3(4):475-83.
8. Xue X, Lai KT, Huang JF, Gu Y, Karlsson L, Fourie A. Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib. J Pharmacol Exp Ther. 2006;317(1):53-60.
9. Degeorge KC, Degeorge BR Jr, Testa JS, Rothstein JL. Inhibition of oncogeneinduced inflammatory chemokines using a farnesyltransferase inhibitor. J Inflamm (Lond). 2008;5:3.
10. Mor A, Keren G, Kloog Y, George J. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. Eur J Immunol. 2008;38(6): 1493-502.
11. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, et al. Inhibition of CD4+CD25+ regulatory T cell function by calcineurin dependent interleukin-2 production. Blood. 2006;108(1):390-9.
12. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995; 333(10):621-7.
13. Leonhardt F, Zirlik K, Buchner M, Prinz G, Hechinger AK, Gerlach UV, et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia. 2012;26(7):1617-29.
14. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens determine graft-versus-host disease phenotype. J Immunol. 2004;173(9): 5467-75.
15. Wilhelm K, Ganesan J, Müller T, Dürr C, Grimm M, Beilhack A, et al. Graft-versushost disease enhanced by extracellular adenosine triphosphate activating P2X7R. Nat Med. 2010;16(12):1434-8.
16. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, et al. Differential impact of mTOR inhibition on CD4+CD25+Foxp3+ regulatory T cells as compared to conventional CD4+ T cells. Blood. 2008;111(1):453-62.
17. Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Negrin RS. HMG-CoA reductase inhibitors (statins) provide acute-graftversus-host disease protection by Th-2 cytokine induction while sparing graft-versus-leukemia activity. Blood. 2007;110(13): 4588-98.
18. Dürr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R, et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 2010;70(24):10170-81.
19. Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood. 2007;110(7):2674-84.
20. Basso AD, Mirza A, Liu G, Long BJ, Bishop WR, Kirschmeier P. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem. 2005;280(35):31101-8.
21. Bachmann MF, Wolint P, Schwarz K, Jäger P, Oxenius A. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol. 2005;175(7): 4686-96.
22. Baars PA, Sierro S, Arens R, Tesselaar K, Hooibrink B, Klenerman P, et al. Properties of murine (CD8+)CD27-T cells. Eur J Immunol. 2005;35(11):3131-41.
23. Voehringer D, Koschella M, Pircher H. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood. 2002;100(10):3698-702.
24. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296-307.
25. Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med. 2011;89(9):833-45.
26. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. 2007;13(8): 913-9.
27. Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli M, et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal. 2008;1(39):ra6.
28. Turner CM, Tam FW, Lai PC, Tarzi RM, Burnstock G, Pusey CD, et al. Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial Transplant. 2007;22(2):386-95.
29. Marks RE, Ho AW, Robbel C, Kuna T, Berk S, Gajewski TF. Farnesyltransferase inhibitors inhibit T cell cytokine production at the post-transcriptional level. Blood. 2007;110(6):1982-8.
30. Lu SXLu SX, Alpdogan O, Lin J, Balderas R, Campos-Gonzalez R, Wang X, et al. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versushost disease. Blood. 2008;112(13):5254-8.
31. Wang S, Guan Q, Diao H, Lian D, Zhong R, Jevnikar AM, Du C. Prolongation of cardiac allograft survival by inhibition of ERK1/2 signaling in a mouse model. Transplantation. 2007;83(3):323-32.
32. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem. 1995;270(45): 26802-6.
33. Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem. 1999;42(8):1333-40.
34. Na IK, Lu SX, Yim NL, Goldberg GL, Tsai J, Rao U, et al. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest. 2010;120(1):343-56.
35. Weinberg K, Blazar BR, Wagner JE, Agura E, Hill BJ, Smogorzewska M, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001;97(5):1458-66.
36. Hindryckx P, De Vos M, Jacques P, Ferdinande L, Peeters H, Olievier K, et al. Hydroxylase inhibition abrogates TNFalpha-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. J Immunol. 2010;185 (10):6306-16.
37. Hauri-Hohl MM, Keller MP, Gill J, Hafen K, Pachlatko E, Boulay T, et al. Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation. Blood. 2007;109 (9):4080-8.
38. Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, et al. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(12):1513-22.
39. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003;102 (13):4255-60.
40. Si MSSi MS, Ji P, Lee M, Kwok J, Kusumoto J, Naasz E, et al. Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. J Heart Lung Transplant. 2005;24 (9):1403-9.
41. Bernier M, Kwon YK, Pandey SK, Zhu TN, Zhao RJ, Maciuk A, et al. Binding of manumycin A inhibits IkappaB kinase beta activity. J Biol Chem. 2006;281(5):2551-61.
42. Takada Y, Khuri FR, Aggarwal BB. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NFkappaB-regulated gene expression and upregulation of apoptosis. J Biol Chem. 2004;279(25):26287-99.
43. Karp JE, Vener TI, Raponi M, Ritchie EK, Smith BD, Gore SD, et al. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2012;119(1):55-63.
44. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinicallaboratory correlative trial. Blood. 2001;97 (1):3361-9.